A password will be e-mailed to you.

Cronos Group (CRON) – Get Report dropped Tuesday after Stifel analyst W. Andrew Carter downgraded his rating on shares of the medical marijuana producer to hold from buy and cut his share price target. The problem: “Uncertainty surrounding the company’s inability to file its SEC filings and the investigation around its revenue recognition practices,” Carter wrote in a report. The company said last week it would delay its earnings release scheduled for Feb. 27 to March 17. The delay stemmed from a “review by the Audit Committee of the Company’s Board of Directors, with the assistance of outside counsel and forensic accountants, of several bulk resin purchases and sales of products through the wholesale channel and the appropriateness of the recognition of revenue from those transactions,” the company said. Cronos Gets Downgrade and Price Target Cut From Stifel

thumbnail courtesy of thestreet.com